Establishing PK biocomparability continues to be an important challenge for the pharmaceutical and biotech industry. Overcoming the challenges within biologic therapeutics have led to many innovative bioanalytical approaches. One such approach was using a monoclonal antibody called siltuximab.

Today, we wanted to share a presentation deck titled “An Innovative Approach for Effective Clinical Evaluation of PK Biocomparability” from Chao Han at J & J. Mr Han delivered this talk at one of our past Controlled & Modified Drug Summits. This presentation will give a brief overview of regulatory requirements, current practice & challenges for biologics and present data on an innovative approach using siltuximab, including presenting the results of a PoC animal study

Scroll through the presentation below……

2021 Global Drug Bioavailability Enhancement Summit

(OCT 12-13, 2021)


Interested to improve the performance of your drug products? Learn 2 years of new drug product development approaches at the 2021 Global Drug Bioavailability Enhancement Virtual Summit this October.

Join 100’s of leading drug delivery, formulation and development experts and hear 25+ expert sessions. Gain over 2 years worth of new drug product development strategies, formulation approaches, delivery technologies and regulatory updates while decreasing drug product time-to-market in just 2 short days (all available on-demand)!

Save over 38% on attendance registration before September 10th, 2021 (Only $309). Likewise, have a platform technology you would like to explore showcasing to the wider audience this October? Reach out below to find out remaining opportunities.

2021 On-Demand Summits Available for Purchase

(Limited time – Only $299)

Pin It on Pinterest

Share This

Share this with a friend or colleague!